2
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
195
Neoplasm Metastasis
22
Prostatic Neoplasms, Castration-Resistant
20
Breast Neoplasms
19
Neoplasms
18
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Triple Negative Breast Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Colorectal Neoplasms
5
Castration-resistant Prostate Cancer
5
Carcinoma, Non-Small-Cell Lung
5
Melanoma
4
Carcinoma, Hepatocellular
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Prostate Adenocarcinoma
3
Ovarian Neoplasms
3
Carcinoma, Renal Cell
3
mCRPC
2
Uterine Cervical Neoplasms
2
Recurrence
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Interventions
darolutamide
4
enzalutamide
2
apalutamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Non-metastatic Castration-resistant Prostate Cancer
×
enzalutamide
×
Clear all
NCT06013475
2025-06-12
DEAR-EXT
Bayer
Completed
1,375 enrolled
NCT05362149
2024-03-20
DEAR
Bayer
Completed
870 enrolled